Stockscreener 앱 받기
20.41
1.11%
-0.23
시간 외 거래:
20.41
전일 마감가:
$20.64
열려 있는:
$20.45
하루 거래량:
1.03M
Relative Volume:
1.30
시가총액:
$1.53B
수익:
-
순이익/손실:
$-64.16M
주가수익비율:
-16.07
EPS:
-1.2702
순현금흐름:
$-69.06M
1주 성능:
+1.74%
1개월 성능:
-24.55%
6개월 성능:
-44.40%
1년 성능:
-42.25%
1일 변동 폭
$20.24
$21.65
1주일 범위
$19.47
$21.65
52주 변동 폭
$14.80
$46.99
Cg Oncology Inc Stock (CGON) Company Profile
명칭
Cg Oncology Inc
전화
(949) 419-6203
주소
400 SPECTRUM CENTER DRIVE, IRVINE
CGON을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
20.41 | 1.53B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-16 | 개시 | Scotiabank | Sector Perform |
| 2025-01-07 | 개시 | TD Cowen | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-09-23 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-28 | 개시 | ROTH MKM | Buy |
| 2024-06-28 | 개시 | BofA Securities | Buy |
| 2024-02-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-20 | 개시 | Goldman | Neutral |
| 2024-02-20 | 개시 | Morgan Stanley | Overweight |
| 2024-02-14 | 개시 | H.C. Wainwright | Buy |
모두보기
Cg Oncology Inc 주식(CGON)의 최신 뉴스
CG Oncology, Inc. (NASDAQ:CGON) Shares Acquired by JPMorgan Chase & Co. - Defense World
CG Oncology (NASDAQ:CGON) Coverage Initiated at Scotiabank - Defense World
Geode Capital Management LLC Has $33.18 Million Stock Position in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology initiated with a Sector Perform at Scotiabank - TipRanks
Scotiabank Initiates Coverage of CG Oncology (CGON) with Sector Perform Recommendation - Nasdaq
Scotiabank Initiates CG Oncology at Sector Perform With $23 Price Target - marketscreener.com
CG Oncology (CGON) vs. Its Competitors Financial Comparison - Defense World
KLP Kapitalforvaltning AS Takes $100,000 Position in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Receives Average Rating of “Buy” from Analysts - Defense World
CG Oncology stock hits 52-week low at $15.7 amid market challenges - Investing.com UK
CG Oncology’s SWOT analysis: bladder cancer stock races against competition By Investing.com - Investing.com South Africa
CG Oncology's SWOT analysis: bladder cancer stock races against competition - Investing.com
CG Oncology’s SWOT analysis: bladder cancer stock races against competition - Investing.com India
CG Oncology's SWOT analysis: bladder cancer stock races against competition By Investing.com - Investing.com South Africa
Vanguard Group Inc. Has $168.10 Million Stock Position in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Reviewing CG Oncology (CGON) and Its Competitors - Defense World
Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade - MSN
Q1 Earnings Estimate for CG Oncology Issued By HC Wainwright - Defense World
Cantor Fitzgerald Weighs in on CG Oncology FY2025 Earnings - Defense World
HC Wainwright Forecasts CG Oncology FY2029 Earnings - Defense World
CG Oncology Looks Attractive At Current Prices (Rating Upgrade) (NASDAQ:CGON) - Seeking Alpha
Teacher Retirement System of Texas Acquires Shares of 11,927 CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Relative Strength Alert For CG Oncology - Nasdaq
CG Oncology stock hits 52-week low at $23.9 amid challenges - Investing.com UK
CG Oncology (NASDAQ:CGON) Receives “Buy” Rating from HC Wainwright - Defense World
HC Wainwright maintains CG Oncology stock Buy rating, $75 target By Investing.com - Investing.com Canada
Practice-Changing Bladder Cancer Results: Key BOND-003 Trial Data Revealed at Major Urology Conference - Stock Titan
CG Oncology announces mixed shelf offering - MSN
CG Oncology Advances in Bladder Cancer Therapeutics - MSN
CG Oncology Full Year 2024 Earnings: Misses Expectations - Yahoo
CG Oncology Inc Files For Mixed Shelf Offering Size Not Disclosed- SEC Filing - MarketScreener
CG Oncology, Inc. SEC 10-K Report - TradingView
CG Oncology Reports 2024 Year End Financial Results And Provides Business Updates - Marketscreener.com
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates - The Manila Times
Swiss National Bank Has $2.28 Million Position in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Is CG Oncology (CGON) Among the Best IPO Stocks to Buy in 2025? - Insider Monkey
CG Oncology’s (CGON) Buy Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright maintains CG Oncology buy with $75 target By Investing.com - Investing.com Australia
H.C. Wainwright maintains CG Oncology buy with $75 target - Investing.com India
Expert Outlook: CG Oncology Through The Eyes Of 4 Analysts - Benzinga
CG Oncology Shares Rise After Reporting Bladder Cancer Drug Durability in Phase 3 Trial - Marketscreener.com
Cretostimogene shows promise in bladder cancer study By Investing.com - Investing.com Australia
Surrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fund - Endpoints News
Cretostimogene shows promise in bladder cancer study - Investing.com India
CG Oncology Reports Promising BOND-003 Data: 75.5% Complete Response Rate for Cretostimogene in Bladder Cancer Treatment - Nasdaq
Breakthrough: Novel Bladder Cancer Drug Shows 75% Response Rate with 28-Month Durability - Stock Titan
CG Oncology, Inc. (NASDAQ:CGON) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Decreases Stock Holdings in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology (CGON) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Cg Oncology Inc (CGON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
4.32%
자본화:
|
볼륨(24시간):